剂型创新:与龙沙Frank Romanski在CPHI法兰克福的对话(上篇)——PharmTech.com
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One - PharmTech.com
生物技术与制药领域的最新动态
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One - PharmTech.com
India rises to tenth place in Cytiva’s Global Biopharma Index 2025 - Express Pharma
'Hopeful' We'll Find Long-term Solution On China: Illumina CEO - Bloomberg.com
Illumina sales flat in Q3 amid China headwinds as CEO remains 'in dialogue' with agencies - Fierce Biotech
Why Illumina (ILMN) Stock Is Up Today - Yahoo Finance
Agilent selects Adam Elinoff as CFO - MedTech Dive
Thermo Fisher Scientific to Acquire Clario to Provide Deeper Clinical Insights - MedTech Intelligence
Thermo Fisher adds clinical trial tech outfit Clario to goodie bag in $9B deal - Fierce Biotech
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? - Yahoo Finance
Is Roche a Hidden Gem After Its New Immunotherapy Partnerships and Share Price Dip? - Yahoo Finance
Julie Roche named 2025 Fellow of the American Physical Society - Ohio University
Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific - Fierce Biotech
India breaks into top 10 in Cytiva’s 2025 Global Biopharma Index - BioSpectrum India
Illumina Inc. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Illumina (NASDAQ:ILMN) Beats Q3 Sales Expectations - Yahoo Finance
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 - PR Newswire
Agilent to Announce Fourth-Quarter Fiscal Year 2025 Financial Results on Nov. 24 - Business Wire
Q&A: Large-scale commercial expansion at Lonza’s Stein facility - Fierce Pharma
Insights from 3D Liver Models: Rethinking Fatty Liver Disease with Hormone Correction